2 ‘- O-Methyl-5’ – O-DMT-pseuudidine 3 ‘- CE phosphoramidite (CAS: 199737-09-2): High quality phosphoramidite monomers assist in the development of small nucleic acid drugs
Product Overview
2 ‘- O-Methyl-5’ – O-DMT-pseuudidine 3 ‘- CE phosphoramidite (Chinese name: DMT-2’ – OME-PSEUDOURIDINE) is a chemically modified nucleoside phosphoramidite monomer that is a key building block in oligonucleotide synthesis. This product combines 2 ‘- O-methyl modification with pseudouridine (PSI) structure, providing an important tool compound for the development of RNA therapy drugs.
Product Manager Email:ada@coreychem.com
- Product Name: 2′-O-Methyl-5′-O-DMT-pseudouridine 3′-CE phosphoramidite
- MF: C40H49N4O9P
- MW: 760.82
- CAS: 199737-09-2
- Structural formula:

Product Features
Double decoration design
This product adopts a unique molecular design strategy, integrating two key modifications into one molecule:
1. Pseudo uridine modification
Pseudouridine is the most common modified nucleoside in RNA, known as the “fifth nucleotide”. Unlike regular uridine, pseudouridine connects bases and ribose through C5-C1 ‘carbon carbon bonds, which brings multiple advantages due to structural changes:
Add an additional hydrogen bond donor site
Enhance the thermal stability of RNA double strands (Tm value increased by approximately 2 ° C)
Optimizing the spatial conformation of RNA
2 ‘- O-methyl modification
The methoxy modification at the 2 ‘position of ribose is a classic strategy for RNA stability modification, which can:
Significantly enhance RNA’s resistance to nucleases
Reduce the incidence of RNA hydrolysis
Reduce the recognition and activation of the immune system
Product Application
Synthesis of small nucleic acid drugs
Phosphorimide monomer is the core raw material for the production of small nucleic acid drugs, which directly affects the quality and cost of the drugs. This product, as a key synthetic block, is suitable for:
- Small interfering RNA (siRNA): enhances stability and prolongs half-life in vivo
- ASO: Enhance target affinity and reduce off target effects
- Aptamer: Optimizing conformational selectivity
- MRNA vaccine: reduces immunogenicity and improves translation efficiency
The value of nucleic acid drug development
With the booming development of small nucleic acid drugs, the global nucleotide market is expected to continue expanding. In 2023, the global market size of nucleotides (including oligonucleotides and monomers) will reach 730 million US dollars, and China, as the largest producer, will use about 90% of its products for the production of nucleic acid drugs. This product is an ideal choice to meet this market demand due to its excellent chemical stability and biological activity.
Storage and usage recommendations
Storage conditions
Temperature: -20 ° C ± 5 ° C
Environment: Dry, dark, inert gas protection
After opening: It is recommended to use immediately or seal and store at low temperature again
Precautions for use
1. Before use, it should be equilibrated to room temperature to prevent condensation from entering
2. Recommend using anhydrous acetonitrile to prepare the solution
3. Strict control of moisture content is required during the synthesis process
Related Products
We also offer a series of modified nucleoside phosphoramidite monomers:
2 ‘- O-MethylRNA phosphoramidite series
Pseudo uridine (PSI) and N1 methyl pseudo uridine derivatives
5-methylcytidine (m5C) modified monomer
2 ‘- F modified phosphoramidite
Product Manager Email:ada@coreychem.com